AbbVie, Thermo Fisher Scientific, Vertex Pharmaceuticals, Danaher, and Cencora are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that focus on the research, development, and commercialization of biotechnology products, such as pharmaceuticals, medical devices, and diagnostics. These stocks are often characterized by high growth potential alongside significant risk, as their success depends on the unpredictable outcomes of scientific research and regulatory approvals. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of NYSE:ABBV traded down $11.03 during trading on Thursday, hitting $168.81. 5,033,554 shares of the company were exchanged, compared to its average volume of 5,884,193. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. The stock has a market capitalization of $298.61 billion, a P/E ratio of 70.01, a PEG ratio of 1.62 and a beta of 0.55. AbbVie has a 12-month low of $153.58 and a 12-month high of $218.66. The firm's 50 day moving average price is $200.79 and its 200-day moving average price is $188.74.
Read Our Latest Research Report on ABBV
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
TMO traded down $31.51 on Thursday, hitting $422.04. 1,185,843 shares of the company were exchanged, compared to its average volume of 1,679,563. Thermo Fisher Scientific has a fifty-two week low of $409.85 and a fifty-two week high of $627.88. The firm has a market capitalization of $159.22 billion, a P/E ratio of 25.46, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The business's fifty day moving average is $516.75 and its 200 day moving average is $541.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.
Read Our Latest Research Report on TMO
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of VRTX traded down $20.56 during trading hours on Thursday, hitting $461.74. The stock had a trading volume of 869,073 shares, compared to its average volume of 1,317,377. Vertex Pharmaceuticals has a 12-month low of $377.85 and a 12-month high of $519.88. The company's fifty day simple moving average is $484.70 and its 200 day simple moving average is $464.03. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The firm has a market cap of $118.57 billion, a P/E ratio of -209.48, a P/E/G ratio of 2.11 and a beta of 0.50.
Read Our Latest Research Report on VRTX
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
DHR stock traded down $13.65 during mid-day trading on Thursday, hitting $178.24. 1,705,033 shares of the company were exchanged, compared to its average volume of 3,284,413. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The firm has a fifty day simple moving average of $204.91 and a 200 day simple moving average of $231.11. Danaher has a twelve month low of $171.00 and a twelve month high of $281.70. The company has a market capitalization of $127.39 billion, a PE ratio of 33.69, a price-to-earnings-growth ratio of 2.66 and a beta of 0.86.
Read Our Latest Research Report on DHR
Cencora (COR)
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Shares of COR traded up $3.08 during trading hours on Thursday, reaching $276.97. 659,814 shares of the company's stock traded hands, compared to its average volume of 1,494,542. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The firm has a market capitalization of $53.71 billion, a price-to-earnings ratio of 39.27, a P/E/G ratio of 1.31 and a beta of 0.55. The business's fifty day simple moving average is $259.12 and its two-hundred day simple moving average is $244.21. Cencora has a twelve month low of $214.77 and a twelve month high of $296.65.
Read Our Latest Research Report on COR
Further Reading
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
